Kalaris Therapeutics Inc
KLRS
NASDAQ·Healthcare·Biotechnology·Mkt cap $85.1M
$3.90
▼ -1.02%
P/E
-1.93
Mkt Cap
$85.1M
52-Wk Range
$3.03–$11.88
52-Week Range
$3.03 - $11.88
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 15.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary cell therapy platform technology
- Focus on underserved immunocompromised patient populations
- Novel approach to restoring natural immunity
- Early-stage pipeline with multiple development programs
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Stable outlook
Advancement through clinical development stages
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-12.2% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying KLRS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.48 vs -$0.50 consensus (+3.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+3.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Jun 15, 2026
vs Industry
How KLRS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.